40 patents
Utility
Neurodevelopmental disorder therapy
12 Dec 23
This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders.
Christopher U. Missling
Filed: 17 Aug 22
Utility
A2-73 as a therapeutic for insomnia, anxiety, and agitation
14 Nov 23
A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation.
Christopher U. Missling
Filed: 23 May 22
Utility
A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy
28 Sep 23
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED.
Christopher U. Missling, Cameron Durrant
Filed: 18 May 23
Utility
Crystal Forms of Tetrahydro-n, N-DIMETHYL-2, 2-DIPHENYL-3-FURANMETHANAMINE, Processes of Making Such Forms, and Their Pharmaceutical Compositions
7 Sep 23
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX19-144) are disclosed and characterized.
Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York, Alani Selvey
Filed: 8 May 23
Utility
A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
4 Jul 23
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED.
Christopher U. Missling, Cameron Durrant
Filed: 26 Oct 20
Utility
Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
30 May 23
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized.
Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York, Alani Selvey
Filed: 5 Apr 21
Utility
A2-73 Crystalline Polymorph Compositions of Matter and Methods of Use Thereof
11 May 23
The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms.
Christopher U. MISSLING, Alani SELVEY
Filed: 1 Nov 22
Utility
Sigma-1 receptor agonist systolic blood pressure therapy
11 Apr 23
A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
Christopher U. Missling
Filed: 28 Nov 18
Utility
Enantiomers of A2-73, analogues, and sigma agonist activity
4 Apr 23
Gervais Neliat
Filed: 19 Jul 16
Utility
SIGMA-1 Receptor Agonist Systolic Blood Pressure Therapy
9 Mar 23
A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
Christopher U. MISSLING
Filed: 14 Nov 22
Utility
Enantiomers of A2-73, Analogues, and Sigma Agonist Activity
9 Feb 23
Gervais Neliat
Filed: 4 Oct 22
Utility
Neurodevelopmental Disorder Therapy
8 Dec 22
This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders.
Christopher U. Missling
Filed: 17 Aug 22
Utility
A2-73 crystalline polymorph compositions of matter and methods of use thereof
15 Nov 22
The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms.
Christopher U. Missling, Alani Selvey
Filed: 12 Apr 19
Utility
A2-73 As a Therapeutic for Insomnia, Anxiety, and Agitation
3 Nov 22
A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation.
Christopher U. Missling
Filed: 23 May 22
Utility
Neurodevelopmental disorder therapy
20 Sep 22
This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders.
Christopher U. Missling
Filed: 8 Jan 21
Utility
ANAVEX2-73 for the Treatment of Genetic Neurodevelopmental Disorders
11 Aug 22
The present invention provides methods for treating a genetic neurodevelopmental disorder such as Rett syndrome, comprising administering to a subject in need thereof a liquid oral dosage formulation comprising a therapeutically effective amount of ANAVEX2-73.
Christopher U. Missling, Alani Selvey
Filed: 22 Jul 20
Utility
Optimized SIGMA-1 Agonist Method of Responder Selection and Treatment
21 Jul 22
The present disclosure provides genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy.
Christopher U. MISSLING, Mohammad Michel AFSHAR, Frédéric PARMENTIER
Filed: 20 May 19
Utility
A2-73 as a therapeutic for insomnia, anxiety, and agitation
24 May 22
A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation.
Christopher U. Missling
Filed: 27 Jul 17
Utility
ANAVEX2-73 for the Treatment of Genetic Neurodevelopmental Disorders
12 May 22
The present invention provides methods for treating a genetic neurodevelopmental disorder, such as Rett syndrome or Fragile X-syndrome, comprising evaluating a subject for his/her occurrence and/or severity of symptoms and/or specific biomarker levels before administering a dosage formulation of ANAVEX2-73 to the subject, administering the dosage formulation of ANAVEX2-73 to the subject for a period of time, re-evaluating the occurrence and/or severity of symptoms and/or specific biomarker levels, and optionally modifying the dosage of ANAVEX2-73 administered to the subject based on the re-evaluation results.
Christopher U. Missling, Alani Selvey
Filed: 21 Jan 22
Utility
Treatment of Cardiac Dysfunction
31 Mar 22
A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or a pharmaceutically acceptable salt thereof or a combination thereof.
Christopher U. Missling
Filed: 26 Jul 21